Article: Precocious puberty treated by hormone. (histrelin acetate)

WASHINGTON, D.C. A synthetic hormone called histrelin acetate was recently approved to treat central, or unexplained, precocious puberty, in which young children develop the sexual characteristics of adolescents.

About 6,000 American children have this condition, with 2,000 new cases diagnosed each year. Histrelin acetate was developed as an orphan product by Ortho Pharmaceuticals of Raritan, N.J., and will be marketed under the brand name Supprelin. Orphan status provides incentives for companies to develop products for use in conditions that afflict fewer than 200,000 people.

In idiopathic central precocious puberty, the most common form of precocious ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!